Connect with us

Technology

Biobanking Market size is set to grow by USD 1.66 billion from 2024-2028, Growing demand for personalized medicine boost the market, Technavio

Published

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global biobanking market size is estimated to grow by USD 1.66 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.04% during the forecast period. Growing demand for personalized medicine is driving market growth, with a trend towards emergence of stem cells storage in biobanks. However, increasing ethical issues poses a challenge. Key market players include AMS Biotechnology Europe Ltd., ASKION GmbH, Azenta Inc., Bay Biosciences LLC, BioIVT LLC, Boca Biolistics LLC, CTIBiotech, Cureline Inc., Danaher Corp., Firalis SA, GENETICIST Inc., Greiner Bio One International GmbH, Hamilton Co., OraSure Technologies Inc., PHC Holdings Corp., Promega Corp., ProteoGenex Inc., Shanghai Genext Medical Technology Co. Ltd., Thermo Fisher Scientific Inc., and US Biolab Corp. Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Biobanking Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.04%

Market growth 2024-2028

USD 1669.1 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

8.36

Regional analysis

Europe, North America, Asia, and Rest of World (ROW)

Performing market contribution

Europe at 38%

Key countries

US, Germany, Japan, UK, and China

Key companies profiled

AMS Biotechnology Europe Ltd., ASKION GmbH, Azenta Inc., Bay Biosciences LLC, BioIVT LLC, Boca Biolistics LLC, CTIBiotech, Cureline Inc., Danaher Corp., Firalis SA, GENETICIST Inc., Greiner Bio One International GmbH, Hamilton Co., OraSure Technologies Inc., PHC Holdings Corp., Promega Corp., ProteoGenex Inc., Shanghai Genext Medical Technology Co. Ltd., Thermo Fisher Scientific Inc., and US Biolab Corp. Inc.

Market Driver

The biobanking market is experiencing significant growth due to the increasing demand for stem cell storage. Stem cells have the potential to address various medical needs in sectors like cardiology and oncology. New biobanking facilities, such as those launched by the Global Stem Cells Group in Chile, are dedicated to stem cell research to improve access to novel therapeutic resources. Research organizations are also investing in advanced production units to enhance supply chain efficiency and increase production capacities. Technological advancements, like IT in logistics and temperature-controlled solutions, minimize errors and enable large-scale stem cell therapy product manufacturing in a sterile environment. These investments present substantial growth opportunities for the biobanking market. 

The Biobanking Market is witnessing significant growth due to the increasing demand for human samples, particularly in the areas of blood, plasma, serum, urine, tissues, and cells. Disease-oriented biobanks and population-based biobanks are major segments, with cancer, respiratory diseases, and Alzheimer’s disease being key focus areas. Sustainability and financial support from public organizations are crucial for the industry’s growth. Tissue banks, blood banks, and stem cell biobanks are key players. Biobanking plays a vital role in drug development, and the life science segment is a significant consumer. Ethical challenges, regulatory scrutiny, and informed consent are crucial considerations. Technidata Medical Software and academic institutions are important partners. Emerging countries offer opportunities, but cold chain logistics and lab processing require attention. Biobanking technologies are advancing, enabling precision/personalized medicine, genetic testing, and regenerative medicines. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

Biobanking, the process of collecting, storing, and managing biological samples for research and diagnostic purposes, faces ethical concerns regarding privacy and consent. Informed consent is crucial to protect individuals’ identities. However, there are debates over the use of biobank data by private companies for their interests. Ethical issues surround the research on biological samples, particularly human embryonic stem cells, including cloning, embryo destruction, and safety concerns. These debates and disagreements may hinder the growth of the global biobanking market, as they impact research and decision-making in various countries.The biobanking market presents both challenges and opportunities for smaller companies with limited financial resources. One major barrier to entry is the high investment required for infrastructure, including automated storage systems and tissue processing facilities. Ongoing maintenance, operational costs, software updates, and repairs add to the financial burden. Training of skilled resources is also essential for effective collection, storage management, sample distribution, and administration. Developed markets offer lucrative opportunities, but high operational costs can be a challenge. New technologies and availability of biospecimens for research present opportunities, but availability and effective collection come with their own set of challenges. The long-term economic situation requires careful consideration of costs associated with in-case collection, tissue processing, and storage management. Low-cost manufacturing advantage can help smaller companies compete, but they must stay updated with the latest technologies to remain competitive.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This biobanking market report extensively covers market segmentation by

Type 1.1 Physical1.2 VirtualProduct 2.1 Equipment2.2 ConsumablesGeography 3.1 Europe3.2 North America3.3 Asia3.4 Rest of World (ROW)

1.1 Physical- The Biobanking Market is a significant industry that focuses on collecting, storing, and managing biological samples for research and diagnostic purposes. Companies in this market provide services such as sample collection, processing, and long-term storage. Key players include Thermo Fisher Scientific, Qiagen, and Corning Incorporated. Market growth is driven by increasing research and development activities in the healthcare sector and advancements in biotechnology. Biobanks play a crucial role in enabling personalized medicine and drug discovery.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The biobanking market encompasses the collection, processing, storage, and distribution of human samples, including blood, plasma, serum, urine, tissues, and cells, for research and diagnostic purposes. Two main types of biobanks exist: disease-oriented and population-based. Disease-oriented biobanks focus on specific diseases, such as cancer, respiratory diseases, and Alzheimer’s disease, while population-based biobanks collect samples from large and diverse populations. Tissue banks and blood banks are specialized types of biobanks. Biobanking plays a crucial role in drug development, particularly in the fields of regenerative medicines, cancer, and personalized medicine. Sustainability, financial support from public organizations, and ethical challenges, including informed consent and sample storage, are key considerations. Technidata Medical Software and academic institutions also contribute to the biobanking landscape. Stem cell biobanks are a significant segment of the market, with potential applications in regenerative medicine. Ethical challenges, such as ensuring informed consent and maintaining sample integrity, must be addressed to ensure the success and legitimacy of biobanking initiatives.

Market Research Overview

The Biobanking Market encompasses the collection, processing, storage, and distribution of human biological samples, including blood, plasma, serum, urine, tissues, and cells. Biobanks come in various forms such as disease-oriented, population-based, tissue, blood, and stem cell biobanks. The market caters to diverse applications like drug development, cancer, respiratory diseases, Alzheimer’s disease, and regenerative medicines. Sustainability and financial support from public organizations are crucial. Technidata Medical Software and other biobanking technologies facilitate efficient operations. Ethical challenges and emerging countries pose barriers to entry for smaller biobanking companies with limited financial resources. Informed consent, sample storage, and lab processing are key considerations. The Blood segment and Cells & Tissue segment dominate the Life Science segment. Precision/personalized medicine, genetic testing, biomedical research, and genetic studies are significant applications. The Biobanking Industry faces regulatory scrutiny and high operational costs, but also offers lucrative opportunities due to new technologies and low-cost manufacturing advantages. Ongoing maintenance, software updates, repairs, and training are essential for biobanking operations. The funding scenario is dynamic, with investments and funding influencing buying behavior. Newborn biobanks and automated equipment contribute to efficiency and quality. Biobanking operations require skilled resources and adherence to regulatory guidelines. Biospecimens are vital for research, and new technologies aim to improve availability.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

TypePhysicalVirtualProductEquipmentConsumablesGeographyEuropeNorth AmericaAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/biobanking-market-size-is-set-to-grow-by-usd-1-66-billion-from-2024-2028–growing-demand-for-personalized-medicine-boost-the-market-technavio-302210033.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Bloomberg Introduces Spread-to-Benchmark Quoting for EUR and GBP Portfolio Trading Baskets

Published

on

By

LONDON, June 2, 2026 /PRNewswire/ — Bloomberg today announced the launch of Spread-to-Benchmark quoting and trading for Euro (EUR) and Sterling (GBP) denominated portfolio trades through its Portfolio Trading Basket Builder (PTBB). The new functionality expands the range of quoting protocols available for European credit portfolio trading and reflects growing client demand for spread-based execution workflows, alongside increased dealer support for the convention across EUR and GBP markets.

Spread-to-Benchmark quoting is a well-established protocol for USD credit portfolio trades and is used by market participants to evaluate and execute portfolio trades. By extending this workflow to EUR and GBP portfolio trades, Bloomberg enables clients and dealers to transact using a familiar spread-based methodology across additional credit markets. 

The introduction of Spread-to-Benchmark quoting for EUR and GBP baskets reflects increased client interest in evaluating portfolio trades through a spread-based lens and the growing adoption of spread-based execution workflows in European credit markets. The workflow provides market participants with an additional framework for assessing the relationship between credit spread risk and underlying government bond yields when pricing and executing portfolio trades. 

Additional Workflow Flexibility 
The workflow complements Bloomberg’s existing portfolio trading capabilities, which support the full range of market-standard quoting conventions, including Price, Yield, Spread-to-Benchmark and Spread based workflows that reference Bloomberg’s evaluated pricing service (BVAL). This gives clients flexibility to compare and execute portfolio trades using the quoting methodology that best aligns with their investment objectives, execution preferences and internal risk management processes. 

“European credit clients continue to look for execution workflows that reflect how they evaluate risk and monitor portfolio trading outcomes,” said Harry Street, Global Head of Credit and Equities Trading Product at Bloomberg. “By expanding dealer support for Spread-to-Benchmark quoting for EUR and GBP baskets, Bloomberg is broadening the range of workflow options available to clients trading European credit portfolios.” 

“Portfolio trading workflows in fixed income continue to become more sophisticated as institutional investors look for ways to evaluate execution quality in changing market conditions,” said Kevin McPartland, Head of Market Structure & Technology Research at Crisil Coalition Greenwich. “Spread-based quoting helps market participants more clearly distinguish between the impacts of credit spread and underlying rates movements when determining how best to execute a portfolio trade.” 

Bloomberg’s Electronic Markets solutions are used by leading financial institutions to trade efficiently in over 175 markets around the world. More than 9,000 client firms use Bloomberg Electronic Markets to access industry-leading depth and breadth of liquidity across asset classes from over 800 dealers globally. Bloomberg Electronic Markets provides market participants with comprehensive solutions across the trading lifecycle, including robust price transparency, analytics, automation and execution, powered by Bloomberg’s high-quality, multi-asset class data and tools.

About Bloomberg
Bloomberg is a global leader in business and financial information, delivering trusted data, news, and insights that bring transparency, efficiency, and fairness to markets. The company helps connect influential communities across the global financial ecosystem via reliable technology solutions that enable our customers to make more informed decisions and foster better collaboration. For more information, visit Bloomberg.com/company or request a demo.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bloomberg-introduces-spread-to-benchmark-quoting-for-eur-and-gbp-portfolio-trading-baskets-302787922.html

SOURCE Bloomberg L.P.

Continue Reading

Technology

Dr. Sunho Kang, a senior battery-technology executive with leadership experience at major global battery and EV manufacturers, joins TeraWatt Technology as Head of Product and Technology

Published

on

By

SAN FRANCISCO, June 2, 2026 /PRNewswire/ — TeraWatt Technology Inc. (Headquartered in California, USA) is pleased to announce that Dr. Sunho Kang has joined the company as Head of Product and Technology.

Dr. Kang is a globally recognized battery-technology executive with more than 25 years of leadership experience spanning the United States, Asia, and Europe, and a distinguished track record of advancing innovations from laboratory research through gigafactory-scale production. He has held senior executive positions at world-leading organizations including Samsung SDI, Apple, and Volkswagen Group of America, and brings deep expertise in lithium-ion battery materials, cell engineering, and product industrialization across a broad range of applications, including electric vehicles and energy storage systems.

At TeraWatt, Dr. Kang will lead global product development and the commercialization of TeraWatt’s battery technology platform, aiming to accelerate the delivery of TeraWatt’s competitive products as well as the technology and commercialization roadmap including manufacturing scale-up.

Dr. Kang commented:

“I am thrilled to join TeraWatt Technology as Head of Product and Technology. TeraWatt’s innovative battery platform presents a tremendous opportunity to push the boundaries of lithium-ion technology, and I look forward to working with the team to accelerate product development and commercialization to deliver meaningful impact.”

TeraWatt Technology founder CEO Ken Ogata, Ph.D. commented:

“We are thrilled to welcome Dr. Kang as our Head of Product and Technology. His deep expertise in battery materials, cell engineering, and productization will be instrumental in accelerating TeraWatt’s product roadmap and technology leadership. Together with Dr. Kang, we will continue to drive our mission forward.”

About TeraWatt Technology Inc.
TeraWatt Technology Inc. is a California-based company that produces lightweight, high-power, and safe next-generation lithium-ion batteries.

Company Overview
Name: TeraWatt Technology Inc.
Representative: Co-founder and CEO Ken Ogata
Headquarters: 28 Geary St, Suite 650, San Francisco, CA 94108, United States
Founded: January 2020
Established: December 2019
URL: https://www.terawatt-technology.com/

 

View original content:https://www.prnewswire.com/news-releases/dr-sunho-kang-a-senior-battery-technology-executive-with-leadership-experience-at-major-global-battery-and-ev-manufacturers-joins-terawatt-technology-as-head-of-product-and-technology-302786854.html

SOURCE TeraWatt Technology Inc.

Continue Reading

Technology

Tencent Cloud and Soniox Announce Strategic Partnership: Combining Advanced Speech-to-Text (STT) Technology with Global Real-Time Infrastructure

Published

on

By

HONG KONG, June 2, 2026 /PRNewswire/ — Tencent Cloud, the cloud business of global technology company Tencent, today announced a strategic partnership with Soniox, a San Francisco-based speech AI company that specializes in developing high-accuracy, low-latency speech AI solutions. The collaboration integrates Soniox’s speech-to-text (STT) technology with Tencent Cloud’s Real-Time Communication (TRTC) enterprise-grade global infrastructure, enabling enterprises to build and deploy multilingual voice AI applications across 200+ countries and regions.

Elevating Enterprise Voice AI at a Global Scale

In enterprise voice AI deployments, latency directly affects user experience and application reliability. The integration of Soniox’s high-accuracy, low-latency STT with TRTC’s global transmission infrastructure reduces latency across the entire pipeline, creating a comprehensive end-to-end solution for enterprises deploying conversational AI applications worldwide.    

Soniox is the voice platform for every language. Unlike legacy speech AI, which was built primarily for English-speakers, Soniox delivers native-speaker accuracy across 60+ languages. Its technology can handle mid-sentence language switching — a user can switch between English and Chinese in a single utterance, and Soniox will capture every word with complete accuracy. All of this works through a single API that works for both speech-to-text and text-to-speech.

By integrating TRTC, the partnership leverages an enterprise-grade real-time communication backbone featuring more than 3,200 global nodes, sub-300 ms worldwide latency, and advanced capabilities such as AI noise suppression and weak-network resilience. These capabilities enable conversational AI applications to operate reliably across diverse network environments, including regions such as Southeast Asia and Africa.

With the roll out of this partnership, developers can integrate the Soniox STT API directly within the Tencent Cloud console. Whether targeting English-speaking markets or supporting languages such as Arabic, Hindi, and Malay, enterprises can build global voice applications — including intelligent customer service, voice assistants, real-time translation, and meeting transcription — to address the demands of expansion into emerging markets and multilingual scenarios.

Wison Xie, Head of Product at Tencent RTC, stated: “Tencent RTC has always been committed to providing reliable real-time communication infrastructure for global enterprises. Our partnership with Soniox brings together our strengths in enterprise-grade audio transmission and Soniox’s advanced speech recognition technology. Together, we are making it easier for businesses to deploy accurate, low-latency voice AI applications across any language and any market.”

Klemen Simonic, CEO at Soniox Inc., stated “At Soniox, our mission is to help businesses understand every word, in any language, with native speaker accuracy and exceptional speed. Partnering with Tencent Cloud combines our speech AI with world-class real-time infrastructure, enabling enterprises to build voice AI experiences that scale globally with low latency and reliability.”

About Tencent Cloud:

Tencent Cloud, one of the world’s leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI, IoT, and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel, and transportation.

About Tencent RTC:

Tencent RTC provides real-time communication solutions, including audio/video calling, live streaming, and in-game voice. With enterprise-grade security, AI-powered enhancements, and a global network of over 3,200 nodes, Tencent RTC powers mission-critical communication for customers worldwide.

About Soniox:

Soniox is a next-generation voice AI company bringing about the end of English-first speech AI. Most people on the planet did not grow up speaking English and often mix languages mid-sentence; and yet legacy speech AI was built for just English. Soniox is different: native-speaker accuracy across 60+ languages, true mid-sentence language switching, and flawless alphanumeric recognition that legacy providers still can’t match. For developers building global apps, Soniox is the only option. Try it for yourself at soniox.com.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/tencent-cloud-and-soniox-announce-strategic-partnership-combining-advanced-speech-to-text-stt-technology-with-global-real-time-infrastructure-302786832.html

SOURCE Tencent Cloud

Continue Reading

Trending